 Connection
Michael Szarek to Brain Ischemia
This is a "connection" page, showing publications Michael Szarek has written about Brain Ischemia.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.951 |
|
|
|
-
Anand SS, Hiatt W, Dyal L, Bauersachs R, Berkowitz SD, Branch KRH, Debus S, Fox KAA, Liang Y, Muehlhofer E, Nehler M, Haskell LP, Patel M, Szarek M, Yusuf S, Eikelboom J, Bonaca MP. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. Eur J Prev Cardiol. 2022 05 05; 29(5):e181-e189.
Score: 0.153
-
Ostadal P, Steg PG, Poulouin Y, Bhatt DL, Bittner VA, Chua T, Diaz R, Goodman SG, Huo Y, Jukema JW, Karpov Y, Pordy R, Scemama M, Szarek M, White HD, Schwartz GG. Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2022 05; 10(5):330-340.
Score: 0.152
-
Krantz MJ, Debus SE, Hsia J, Patel MR, Anand SS, Nehler MR, Hess CN, Capell WH, Bracken T, Szarek M, M?ty?s L, Krievins DK, Nault P, Stefanov S, Haskell LP, Berkowitz SD, Muehlhofer E, Hiatt WR, Bauersachs RM, Bonaca MP. Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. Eur Heart J. 2021 10 14; 42(39):4040-4048.
Score: 0.147
-
Tu??n J, Steg PG, Bhatt DL, Bittner VA, D?az R, Goodman SG, Jukema JW, Kim YU, Li QH, Mueller C, Parkhomenko A, Pordy R, Sritara P, Szarek M, White HD, Zeiher AM, Schwartz GG. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J. 2020 11 07; 41(42):4114-4123.
Score: 0.138
-
Diaz R, Li QH, Bhatt DL, Bittner VA, Baccara-Dinet MT, Goodman SG, Jukema JW, Kimura T, Parkhomenko A, Pordy R, Reiner ?, Roe MT, Szarek M, Tse HF, White HD, Zahger D, Zeiher AM, Schwartz GG, Steg PG. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. Eur J Prev Cardiol. 2021 03 23; 28(1):33-43.
Score: 0.135
-
Sinnaeve PR, Schwartz GG, Wojdyla DM, Alings M, Bhatt DL, Bittner VA, Chiang CE, Correa Flores RM, Diaz R, Dorobantu M, Goodman SG, Jukema JW, Kim YU, Pordy R, Roe MT, Sy RG, Szarek M, White HD, Zeiher AM, Steg PG. Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis. Eur Heart J. 2020 06 21; 41(24):2248-2258.
Score: 0.134
-
Balucani C, Bianchi R, Ramkishun C, Weedon J, Law S, Szarek M, Rojas-Soto D, Tariq S, Levine SR. Rapidly improving stroke symptoms: a pilot, prospective study. J Stroke Cerebrovasc Dis. 2015 Jun; 24(6):1211-6.
Score: 0.094
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|